IS4731A - Kínólín og kínazólín efnasambönd nytsamleg í meðferð - Google Patents

Kínólín og kínazólín efnasambönd nytsamleg í meðferð

Info

Publication number
IS4731A
IS4731A IS4731A IS4731A IS4731A IS 4731 A IS4731 A IS 4731A IS 4731 A IS4731 A IS 4731A IS 4731 A IS4731 A IS 4731A IS 4731 A IS4731 A IS 4731A
Authority
IS
Iceland
Prior art keywords
quinoline
treatment
compounds useful
quinazoline compounds
quinazoline
Prior art date
Application number
IS4731A
Other languages
English (en)
Inventor
John Collis Alan
Nathan Abraham Fox David
Newman Julie
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of IS4731A publication Critical patent/IS4731A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
IS4731A 1995-12-23 1998-04-29 Kínólín og kínazólín efnasambönd nytsamleg í meðferð IS4731A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy
PCT/EP1996/005609 WO1997023462A1 (en) 1995-12-23 1996-12-05 Quinoline and quinazoline compounds useful in therapy

Publications (1)

Publication Number Publication Date
IS4731A true IS4731A (is) 1998-04-29

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4731A IS4731A (is) 1995-12-23 1998-04-29 Kínólín og kínazólín efnasambönd nytsamleg í meðferð

Country Status (34)

Country Link
US (3) US6103738A (is)
EP (1) EP0877734B1 (is)
JP (1) JP3070958B2 (is)
KR (1) KR19990076693A (is)
AP (1) AP715A (is)
AR (1) AR005166A1 (is)
AT (1) ATE194598T1 (is)
AU (1) AU708979B2 (is)
BG (1) BG102559A (is)
BR (1) BR9612263A (is)
CA (1) CA2236814C (is)
CO (1) CO4480106A1 (is)
CZ (1) CZ197698A3 (is)
DE (1) DE69609353T2 (is)
DK (1) DK0877734T3 (is)
ES (1) ES2151192T3 (is)
GB (1) GB9526546D0 (is)
GR (1) GR3034225T3 (is)
HN (1) HN1996000082A (is)
HR (1) HRP960616A2 (is)
HU (1) HUP9903560A3 (is)
IS (1) IS4731A (is)
MA (1) MA26414A1 (is)
NO (1) NO982913L (is)
NZ (1) NZ325248A (is)
OA (1) OA10703A (is)
PL (1) PL327610A1 (is)
PT (1) PT877734E (is)
SK (1) SK81698A3 (is)
TN (1) TNSN96161A1 (is)
TR (1) TR199801195T2 (is)
WO (1) WO1997023462A1 (is)
YU (1) YU68896A (is)
ZA (1) ZA9610784B (is)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
ES2251512T3 (es) * 2000-08-31 2006-05-01 F. Hoffmann-La Roche Ag Derivados de quinazolina como antagonista adrenergicos alfa-1.
KR100554813B1 (ko) * 2001-01-02 2006-02-22 에프. 호프만-라 로슈 아게 알파 1에이/비 아드레날린성 수용체 길항제로서의퀴나졸론 유도체
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
EP1556381B1 (en) 2002-09-26 2008-02-20 Pfizer Limited Pyrazole amides for treating hiv infections
DE602004015269D1 (de) 2003-04-23 2008-09-04 Glaxo Group Ltd Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
JP5577104B2 (ja) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2009315761A1 (en) 2008-11-14 2010-05-20 F. Hoffmann-La Roche Ag Quinazoline derivatives as NK3 receptor antagonists
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
JP5770158B2 (ja) * 2009-03-23 2015-08-26 シプラ・リミテッド ドキサゾシン及びその塩の製造方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP3575288B1 (en) * 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
US9101696B2 (en) 2011-03-11 2015-08-11 W.L. Gore & Associates, Inc. Immobilised biological entities
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
JP6377245B2 (ja) 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Smo阻害剤としてのキノリン誘導体
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3939591A1 (en) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
RS66416B1 (sr) * 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
OA10703A (en) 2002-11-28
AP9600900A0 (en) 1997-01-31
CZ197698A3 (cs) 1999-03-17
DK0877734T3 (da) 2000-11-20
AU708979B2 (en) 1999-08-19
US20030220332A1 (en) 2003-11-27
KR19990076693A (ko) 1999-10-15
DE69609353D1 (de) 2000-08-17
BR9612263A (pt) 1999-07-13
CA2236814A1 (en) 1997-07-03
ATE194598T1 (de) 2000-07-15
US20020049322A1 (en) 2002-04-25
WO1997023462A1 (en) 1997-07-03
NZ325248A (en) 1999-09-29
EP0877734B1 (en) 2000-07-12
YU68896A (sh) 1999-07-28
GR3034225T3 (en) 2000-12-29
BG102559A (en) 1999-03-31
EP0877734A1 (en) 1998-11-18
US6103738A (en) 2000-08-15
CA2236814C (en) 2001-09-18
GB9526546D0 (en) 1996-02-28
HUP9903560A3 (en) 2000-07-28
JPH11501668A (ja) 1999-02-09
NO982913L (no) 1998-07-30
JP3070958B2 (ja) 2000-07-31
HRP960616A2 (en) 1998-06-30
TNSN96161A1 (fr) 2005-03-15
AR005166A1 (es) 1999-04-14
PT877734E (pt) 2000-12-29
PL327610A1 (en) 1998-12-21
HN1996000082A (es) 1997-06-30
SK81698A3 (en) 2000-04-10
AU1371997A (en) 1997-07-17
MA26414A1 (fr) 2004-12-20
AP715A (en) 1998-12-30
US6642242B2 (en) 2003-11-04
US6750214B2 (en) 2004-06-15
TR199801195T2 (xx) 1998-10-21
NO982913D0 (no) 1998-06-22
CO4480106A1 (es) 1997-07-09
DE69609353T2 (de) 2000-12-07
HUP9903560A2 (hu) 2000-05-28
ES2151192T3 (es) 2000-12-16
ZA9610784B (en) 1998-06-22

Similar Documents

Publication Publication Date Title
IS4731A (is) Kínólín og kínazólín efnasambönd nytsamleg í meðferð
KR960008976A (ko) 처리장치 및 처리방법
DK0915880T3 (da) Azolotriaziner og pyrimidiner
FI970990A7 (fi) Syövän toteaminen ja hoito
ZA98166B (en) Quinoline and quinazoline compounds useful in therapy
DE69827915D1 (de) Verarbeitungsverfahren und -vorrichtung
FI963126L (fi) Stanoliseos ja sen käyttö
FI965161L (fi) Käyttäjän tunnistusmenetelmä ja laite
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
NO307513B1 (no) 2,8-disubstituert chinazolinon og anvendelse derav
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
CY2006007I1 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
DE69708619D1 (de) Elektroentionisierungsvorrichtung und methode
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
NO961346D0 (no) Benzonitriler og benzofluorider
NO980718D0 (no) Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer
DE69736267D1 (de) Plasmabehandlungsvorrichtung und -verfahren
DE69628873D1 (de) Ausrichtgerät und -verfahren
NO984836D0 (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
FI962103A0 (fi) Höyrystyslaite ja menetelmä
DE69620243D1 (de) Haupt- und nebenstromfilter
DE69737490D1 (de) Anzeigegerät und dessen Herstellungsverfahren
DE19882530T1 (de) Kaltformungsverfahren und -vorrichtung
NO983556L (no) Formulering og anvendelse
NO992561D0 (no) Oppslemmingsbehandlingssystem og oppslemmingsbehandlingsmetode